Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study

2023
Written By Guest User
Guest User
Previous

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Next

Epitopea Announces $14 Million Financing